ARTICLE | Company News
Exocell, Boehringer Mannheim GmbH metabolic news
January 27, 1997 8:00 AM UTC
The companies settled an April 1996 suit filed by Exocell in the U.S. District Court of the Eastern District of Pennsylvania, which alleged that statements included in a Boehringer Mannheim patent application were false. According to Exocell, Boehringer Mannheim had asserted that Exocell's A717 monoclonal antibodies did not recognize glycated albumin formed in the body. Under the settlement, Boehringer Mannheim acknowledges and accepts that the MAbs react with glycated albumin formed in the body. ...